Type 1 Diabetes Market for Diagnosed Prevalent Cases to Grow 40.40% to 2023 Says a New Report Available at RnRMarketResearch.com
Dallas, Texas (PRWEB) November 03, 2014 -- Type 1 diabetes, formerly referred to as insulin-dependent diabetes, is a type of diabetes that predominantly develops in children or young adults before the age of 40 years. The condition, therefore, was also referred to as juvenile diabetes. Type 1 diabetes accounts for about 10% of all diabetes cases and occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin – a hormone that regulates blood sugar. If the condition is left untreated, blood sugar levels accumulate. In addition to the pancreas, high levels of blood sugar can damage other major organs, such as the heart, blood vessels, nerves, eyes, and kidneys; such damage can be life threatening. Thus, type 1 diabetes has an immense impact on the physical, psychological, and social well-being of patients. Furthermore, research suggests that the incidence of type 1 diabetes is increasing globally, which may lead to an increased burden on healthcare resources.
Complete report available at http://www.rnrmarketresearch.com/epicast-report-type-1-diabetes-epidemiology-forecast-to-2023-market-report.html.
Type 1 diabetes is a type of diabetes that accounts for 10% of all diabetes cases. The condition occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin a hormone that regulates blood sugar. Type 1 diabetes, formerly referred to as insulin-dependent diabetes, mostly develops in children and young adults. Hence, it has also been called juvenile diabetes, although this term is no longer frequently used.
According to GlobalData’s analysis, the diagnosed prevalent cases of type 1 diabetes in the 8MM will grow by 40.40% over the next decade, from 6.02 million prevalent cases in 2013 to 8.45 million prevalent cases in 2023. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases of type 1 diabetes in the 8MM to environmental factors (seasonal variation) coupled with genetic factors, such as a family history of type 1 diabetes. However, further research is necessary to clearly understand the epidemiological factors responsible for the growth in the prevalent cases of type 1 diabetes.
Order a Purchase copy at http://www.rnrmarketresearch.com/contacts/purchase?rname=235510.
To forecast the diagnosed prevalent cases of type 1 diabetes in the 8MM, GlobalData epidemiologists selected nationally representative population-based studies that provided diagnosed prevalence data in the 8MM. Furthermore, GlobalData epidemiologists segmented the prevalent cases of type 1 diabetes by BMI in each market. These BMI segmentations could provide valuable insight into potential patient populations that are eligible for targeted screening programs.
Scope
• The Type 1 Diabetes EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for type 1 diabetes in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). In addition, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of type 1 diabetes segmented by age (ages 0-14 years,15-29 years, 30-44 years, 45-59 years, 60-74 years, and =75 years) and sex. Furthermore, the report provides the distribution of diagnosed prevalent cases of type 1 diabetes segmented by body mass index (BMI) (kg/m2) (BMI The Type 1 Diabetes epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Inquire for Discount at http://www.rnrmarketresearch.com/contacts/discount?rname=235510. (This is a premium report priced at US$3995 for a single user License.)
Reasons to buy
• Develop business strategies by understanding the trends shaping and driving the global type 1 diabetes market.
• Quantify patient populations in the global type 1 diabetes market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups, sex that present the best opportunities for type 1 diabetes therapeutics in each of the markets covered.
Table of Contents
1 Table of Contents
2 Introduction
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global Trends
3.3.1 US
3.3.2 5EU
3.3.3 Japan
3.3.4 Canada
3.4 Forecast Methodology
3.5 Epidemiological Forecast for Type 1 Diabetes (2013-2023)
3.6 Discussion
4 Appendix
Browse more reports on Diabetes Therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/diabetes-therapeutics.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnRMarketREsearch, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article